Dentons has advised Pelion S.A. on the sale of 100% of shares in Eubioco S.A., a contract manufacturer of medicines, diet supplements, medicinal products, pharmaceutical substances, dermocosmetic products and disinfectant liquids. The shares were sold to Nevu.

Pelion is Poland's largest healthcare sector corporation with annual turnover of more than PLN 9 billion and over 9,000 employees. The Pelion group has approximately 170 subsidiaries.

"Last year Dentons had the opportunity to advise on the tender offer and delisting of Pelion's shares from the Warsaw Stock Exchange. We are delighted that the Pelion Group, a leader in the Polish economy, chose us for this transaction once again," said Jakub Celinski, partner in Dentons Capital Markets and M&A practice in Warsaw.

Dentons provided comprehensive advisory for this transaction, which included the drafting and negotiating of transaction documentation. Jakub Celinski led the Dentons team, ably supported by three Capital Markets and M&A counsel, namely Tomasz Dubij, Ryszard Manteuffel and Marcin Paliwoda.